Abstract
Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70-year-old man treated for vocal cord carcinoma.
| Original language | English |
|---|---|
| Pages (from-to) | 8-9 |
| Number of pages | 2 |
| Journal | Asian Journal of Pharmaceutical and Clinical Research |
| Volume | 10 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 01-04-2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmaceutical Science
- Pharmacology (medical)
Cite this
}
Nimotuzumab-induced hypertension : A maiden case report. / Balaji, Ommurugan; Amita Priya, D.; Patil, Navin.
In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, No. 4, 01.04.2017, p. 8-9.Research output: Contribution to journal › Article
TY - JOUR
T1 - Nimotuzumab-induced hypertension
T2 - A maiden case report
AU - Balaji, Ommurugan
AU - Amita Priya, D.
AU - Patil, Navin
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70-year-old man treated for vocal cord carcinoma.
AB - Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70-year-old man treated for vocal cord carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=85017096097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017096097&partnerID=8YFLogxK
U2 - 10.22159/ajpcr.2017.v10i4.16868
DO - 10.22159/ajpcr.2017.v10i4.16868
M3 - Article
VL - 10
SP - 8
EP - 9
JO - Asian Journal of Pharmaceutical and Clinical Research
JF - Asian Journal of Pharmaceutical and Clinical Research
SN - 0974-2441
IS - 4
ER -